MedPath

Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

Phase 3
Recruiting
Conditions
Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
Interventions
Drug: Placebo
Registration Number
NCT06267560
Lead Sponsor
Novartis Pharmaceuticals
Brief Summary

Study CTQJ230A12303 is a randomized, double-blind placebo-controlled, Phase IIIb study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) 80 mg s.c. QM compared with placebo s.c. QM in US Black/African American and Hispanic participants with established ASCVD and elevated levels of Lp(a) who are treated for cardiovascular (CV) risk factors according to local practice/guidelines for the reduction of cardiovascular risk.

Detailed Description

CTQJ230A12303 is a randomized, double-blind, placebo-controlled, multi-center, Phase IIIb study to evaluate the efficacy ( measured by reduction of the Lp(a) levels) and safety of pelacarsen (TQJ230) 80mg s.c. QM compared to placebo in US Black/African American and US Hispanic participants, with established atherosclerotic cardiovascular disease (ASCVD) as evidenced by history of coronary heart disease, cerebrovascular disease or symptomatic peripheral artery disease (PAD) and elevated levels of Lp(a).

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
400
Inclusion Criteria
  • Male and female US Black/African American and US Hispanic participants 18 to ≤ 80 years of age

  • Lp(a) ≥ 125 nmol/L at the screening visit, measured at the Central laboratory

  • On Standard of Care (SoC) therapy for risk factors other than Lp(a), including LDL-C (LDL-C lowering therapy dose stable for at least 30 days), elevated blood pressure and diabetes, at the randomization visit according to local practice/guidelines.

  • Established ASCVD disease defined as documented:

    • Coronary heart disease (CHD) and/or
    • Cerebrovascular disease (CVD) and/or
    • Peripheral arterial disease (PAD):
Exclusion Criteria
  • Uncontrolled hypertension
  • Heart failure New York Heart Association (NYHA) class IV
  • History of malignancy of any organ system
  • History of hemorrhagic stroke or other major bleeding
  • Platelet count <140,000 per mm3
  • Active liver disease or hepatic dysfunction
  • Significant kidney disease
  • Pregnant or nursing women

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
TQJ230TQJ230TQJ230 80mg QM s.c.
PlaceboPlaceboMatching placebo.
Primary Outcome Measures
NameTimeMethod
Change in log-transformed Lp(a) concentration from baseline at week 52Baseline, week 52

The primary aim of the study is to demonstrate the superiority of pelacarsen to placebo in lowering the Lp(a) level at 12 months of treatment in US Black/African American and US Hispanic participants with established ASCVD and a Lp(a) level of ≥ 125 nmo/L.

Secondary Outcome Measures
NameTimeMethod
Incidence proportion of study discontinuations due to TEAEsUp to 52 weeks

Incidence proportion of study discontinuations due to TEAEs will be provided

Incidence proportion of Treatment emergent adverse events (TEAEs) of special interestUp to 52 weeks

Incidence proportion of Treatment emergent adverse events (TEAEs) of special interest will be provided

Trial Locations

Locations (100)

Synexus Clinical Research Advantage

🇺🇸

Birmingham, Alabama, United States

Parkway Medical Center

🇺🇸

Birmingham, Alabama, United States

Optimal Research LLC

🇺🇸

Huntsville, Alabama, United States

Synexus

🇺🇸

Glendale, Arizona, United States

Cardiology and Medicine Clinic PA

🇺🇸

Little Rock, Arkansas, United States

National Heart Institute

🇺🇸

Beverly Hills, California, United States

Valley Clinical Trials Inc

🇺🇸

Covina, California, United States

NICRs Research Center

🇺🇸

Garden Grove, California, United States

Long Beach Clinical Trials

🇺🇸

Long Beach, California, United States

American Institute of Research

🇺🇸

Los Angeles, California, United States

Angel City Research Inc

🇺🇸

Los Angeles, California, United States

Velocity Clinical Trials

🇺🇸

Los Angeles, California, United States

Acclaim Clinical Research

🇺🇸

San Diego, California, United States

Ventura Heart Institute

🇺🇸

Thousand Oaks, California, United States

Excel Medical Clinical Trials LLC

🇺🇸

Boca Raton, Florida, United States

C and A Clinical Trials

🇺🇸

Cape Coral, Florida, United States

Proactive Clinical Research

🇺🇸

Fort Lauderdale, Florida, United States

National Research Institute

🇺🇸

Hialeah, Florida, United States

Sister Life Research Inc

🇺🇸

Hialeah, Florida, United States

Zenith Clinical Research

🇺🇸

Hollywood, Florida, United States

Inpatient Research Clinical LLC

🇺🇸

Miami Lakes, Florida, United States

Columbus Clinical Services LLC

🇺🇸

Miami, Florida, United States

Finlay Medical Research

🇺🇸

Miami, Florida, United States

International Research Associates, LLC

🇺🇸

Miami, Florida, United States

Baptist Health Medical Group

🇺🇸

Miami, Florida, United States

Clinical Trials of Florida

🇺🇸

Miami, Florida, United States

Eminat LLC

🇺🇸

Miramar, Florida, United States

CTMD Research

🇺🇸

Palm Springs, Florida, United States

DBC Research USA

🇺🇸

Pembroke Pines, Florida, United States

Fam Medical Specialists Of Fl Plc

🇺🇸

Plant City, Florida, United States

TBC Research LLC

🇺🇸

Tamarac, Florida, United States

New Tampa Health

🇺🇸

Tampa, Florida, United States

James A Haley Veterans Hospital

🇺🇸

Tampa, Florida, United States

Cardiology Partners Clinical Research Institute

🇺🇸

Wellington, Florida, United States

Grady Health System

🇺🇸

Atlanta, Georgia, United States

Morehouse School Of Medicine

🇺🇸

Atlanta, Georgia, United States

Atlanta Heart Specialists LLC

🇺🇸

Tucker, Georgia, United States

Synexus Clinical Research US Inc

🇺🇸

Chicago, Illinois, United States

Chicago Clinical Research Inst

🇺🇸

Chicago, Illinois, United States

Flourish Research

🇺🇸

Grandwood Park, Illinois, United States

Cambridge Medical Trials

🇺🇸

Alexandria, Louisiana, United States

Cardiovascular Associates Research

🇺🇸

Covington, Louisiana, United States

Omega Clinical Research

🇺🇸

Metairie, Louisiana, United States

CV Ins of the South

🇺🇸

Opelousas, Louisiana, United States

Southern Clin Research Clinic

🇺🇸

Zachary, Louisiana, United States

Sinai Ct for Throm Res and Drug Dev

🇺🇸

Baltimore, Maryland, United States

Ascension Saint Agnes Heart Care

🇺🇸

Baltimore, Maryland, United States

Johns Hopkins Univ School of Med

🇺🇸

Baltimore, Maryland, United States

Metropolitan Cardiovascular Consultants Llc

🇺🇸

Beltsville, Maryland, United States

Johns Hopkins University

🇺🇸

Columbia, Maryland, United States

Anderson Medical Research

🇺🇸

Fort Washington, Maryland, United States

Capitol Cardiology Associates

🇺🇸

Lanham, Maryland, United States

MD Medical Research

🇺🇸

Oxon Hill, Maryland, United States

Henry Ford Hospital

🇺🇸

Detroit, Michigan, United States

Flint Clinical Research

🇺🇸

Flint, Michigan, United States

Aa Mrc Llc

🇺🇸

Flint, Michigan, United States

Elite Clinical Research LLC

🇺🇸

Jackson, Mississippi, United States

Stern Cardiovascular Foundation Inc

🇺🇸

Southaven, Mississippi, United States

Las Vegas Endocrinology

🇺🇸

Henderson, Nevada, United States

AB Clinical Trials

🇺🇸

Las Vegas, Nevada, United States

Clinical Research of South Nevada

🇺🇸

Las Vegas, Nevada, United States

Robert Wood Johnson Medical School

🇺🇸

New Brunswick, New Jersey, United States

Overlook Medical Center

🇺🇸

Summit, New Jersey, United States

University At Buffalo

🇺🇸

Buffalo, New York, United States

Jamaica Hospital Medical Center

🇺🇸

Jamaica, New York, United States

Mid Hudson Medical Research PLLC

🇺🇸

New Windsor, New York, United States

Wake Forest Health Network LLC

🇺🇸

Asheboro, North Carolina, United States

Monroe Biomedical Research

🇺🇸

Monroe, North Carolina, United States

Velocity Clin Research Springdale

🇺🇸

Cincinnati, Ohio, United States

Hometown Urgent Care and Research

🇺🇸

Columbus, Ohio, United States

NexGen Research

🇺🇸

Lima, Ohio, United States

Care Access Research

🇺🇸

Easton, Pennsylvania, United States

TCV Clinical Studies

🇺🇸

Linwood, Pennsylvania, United States

The Stern Cardiovascular Foundation

🇺🇸

Germantown, Tennessee, United States

Apex Cardiology Research Associates of Jackson

🇺🇸

Jackson, Tennessee, United States

Plano Primary Care Clinic

🇺🇸

Allen, Texas, United States

Pharma Tex Research

🇺🇸

Amarillo, Texas, United States

North Hills Medical Research Inc

🇺🇸

Bedford, Texas, United States

SW Family Medicine Associates

🇺🇸

Dallas, Texas, United States

David Turbay MD PLLC

🇺🇸

El Paso, Texas, United States

Angiocardiac Care of Texas PA

🇺🇸

Houston, Texas, United States

Biopharma Informatic LLC

🇺🇸

Houston, Texas, United States

Epic Clinical Research

🇺🇸

Lewisville, Texas, United States

Discovery Clinical Trials

🇺🇸

Pflugerville, Texas, United States

Clinical Trials of Texas

🇺🇸

San Antonio, Texas, United States

Javara Research

🇺🇸

Alexandria, Virginia, United States

Ctr For Clin Rsrch And Innovation

🇺🇸

Spring, Texas, United States

Sugar Lakes Family Practice

🇺🇸

Sugar Land, Texas, United States

Virginia Heart

🇺🇸

Falls Church, Virginia, United States

Heart Care Associates P C

🇺🇸

Hopewell, Virginia, United States

Dominion Medical Associates

🇺🇸

Richmond, Virginia, United States

Virginia Commonwealth University

🇺🇸

Richmond, Virginia, United States

University of Washington

🇺🇸

Seattle, Washington, United States

Advanced Clinical Research LLC

🇵🇷

Bayamon, Puerto Rico

Dr Yolanda Figueroa Private Pr

🇵🇷

Humacao, Puerto Rico

CAIMED Center

🇵🇷

Ponce, Puerto Rico

Research and Cardiovascular Corp

🇵🇷

Ponce, Puerto Rico

Latin Clinical Trial Center Inc

🇵🇷

San Juan, Puerto Rico

VA Caribbean Healthcare System

🇵🇷

San Juan, Puerto Rico

Advanced Medical Research Center

🇵🇷

San Juan, Puerto Rico

© Copyright 2025. All Rights Reserved by MedPath